Table 1.
Baseline characteristics of the included studies
| Study | Location | Date | Study type* | Sample size | XDR (%) | HIV (%) | Previous therapy (%) | Mean resistance |
|---|---|---|---|---|---|---|---|---|
| Drobac et al [19] |
Peru |
1999-2003 |
RC |
27 |
- |
- |
- |
- |
| Joseph et al [17] |
India |
2006-2007 |
PC |
38 |
0 |
0 |
100 |
3 · 6 |
| Malla et al [22] |
Nepal |
2005-2006 |
RC |
175 |
- |
- |
93 |
3 · 7 |
| Mitnick et al. [20] |
Peru |
1996-1999 |
RC |
75 |
- |
1 · 3 |
100 |
Median 6 |
| Mitnick et al. [21] |
Peru |
1999-2002 |
RC |
651 |
7 · 4 |
1 · 4 |
65 |
5 · 3, 8 · 4 |
| Oyieng’o et al. [24] |
Kenya |
2008-2010 |
RC |
8 |
0 |
50 |
100 |
3 · 1 |
| Satti et al. [25] |
Lesotho |
2007-2011 |
RC |
5 |
0 |
60 |
- |
2.8 |
| Singla et al. [16] |
India |
2002-2006 |
RC |
126 |
- |
0 |
100 |
3 |
| Thomas et al. [18] |
India |
1999-2003 |
PC |
66 |
1 · 5 |
- |
100 |
3 · 4 |
| Tupasi et al. [23] | Philippines | 1999-2002 | RC | 117 | - | - | 96 | - |
*RC = retrospective cohort; PC = prospective cohort.